Clinical Trials Browser

Interventional × cabazitaxel × Genitourinary × Clear all

NCT06353386 2026-03-13

MK-5684-01A

Phase 1/2 Recruiting

Prostatic Neoplasms, Castration-Resistant

NCT03419234 2026-03-12

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Phase 2 Active not recruiting

223 enrolled 14 charts

Prostatic Neoplasms

NCT01616875 2026-03-06

Bristol Bladder Trial

Phase 2 Completed

28 enrolled 21 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02703623 2026-03-06

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06691984 2026-03-06

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Phase 3 Recruiting

Neoplasms, Prostatic Neoplasms

NCT06632977 2026-03-04

PREDICT

Phase 2 Recruiting

Prostatic Neoplasms

NCT06085729 2026-02-27

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

Phase 1/2 Suspended

Prostatic Neoplasms

NCT02522715 2026-02-24

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Phase 1/2 Active not recruiting

37 enrolled 10 charts

Prostatic Neoplasms

NCT03263650 2026-02-17

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Phase 2 Active not recruiting

Prostate Cancer, Hereditary, 7, Prostatic Neoplasms

NCT05818683 2026-02-13

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Phase 1 Recruiting

Metastatic Castration-resistant Prostate Neoplasms

NCT06470243 2026-01-22

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Phase 3 Recruiting

Prostatic Neoplasms

NCT03556904 2026-01-15

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Phase 2 Completed

14 enrolled 16 charts

Prostatic Neoplasms

NCT03258320 2026-01-12

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients

Phase 2/3 Recruiting

Prostatic Neoplasms

NCT04592237 2025-12-23

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02985957 2025-12-22

CheckMate 650

Phase 2 Completed

351 enrolled 43 charts

Prostatic Neoplasms

NCT04709276 2025-09-11

CHAMP

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06738303 2025-08-27

CATCH-177

Phase 2 Recruiting

Prostatic Neoplasms

NCT05005728 2025-07-17

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT01420250 2025-05-15

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT03764540 2025-04-13

CABPOSTAAT

Phase 2 Terminated

Prostatic Neoplasms

NCT03903835 2025-04-09

ProBio

Phase 3 Recruiting

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT05340374 2025-04-06

LuCAB

Phase 1/2 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06890832 2025-03-24

A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer

Phase 2 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer, MCRPC

NCT02218606 2024-12-10

Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

Phase 2 Completed

81 enrolled 11 charts

Prostatic Neoplasms

NCT05762536 2024-06-27

DAROTAXEL

Phase 2 Recruiting

Metastatic Castration-resistant Prostate Cancer

NCT05563558 2024-06-11

PEAPOD_FOS

Phase 2 Recruiting

Prostate Cancer Metastatic

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03934840 2024-02-28

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Phase 2 Completed

40 enrolled 18 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT02543255 2024-01-31

ACDC-RP

Phase 2 Completed

Prostatic Neoplasms

NCT04495179 2023-08-09

AARDVARC

Phase 2 Completed

30 enrolled 22 charts

Prostatic Neoplasms

NCT03114254 2022-11-18

JAVA-P

Phase 2 Completed

Neoplasm Metastasis, Penile Neoplasms, Recurrence

NCT03392428 2022-06-13

TheraP

Phase 2 Completed

Neoplasm Metastasis, Prostatic Neoplasms

NCT02485691 2022-05-27

CARD

Phase 4 Completed

255 enrolled 21 charts

Prostate Cancer Metastatic

NCT02961257 2022-05-12

CABASTY

Phase 3 Completed

Prostate Cancer Metastatic

NCT01650285 2022-03-04

Cabazitaxel and Radiation For Patients With Prostate Cancer

Phase 2 Terminated

5 enrolled 5 charts

Prostatic Neoplasms

NCT03101046 2022-02-10

TACTIK

Phase 2 Completed

Neoplastic Cells, Circulating, Prostatic Neoplasms

NCT03050866 2021-08-20

CABA-V7

Phase 2 Unknown

Neoplastic Cells, Circulating, Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02844582 2021-01-25

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 2 Terminated

2 enrolled 5 charts

Hormone-Resistant Prostate Cancer

NCT04622761 2021-01-05

CHROME

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT03110588 2020-10-19

Phase I Trial of PACE for Metastatic Prostate Cancer

Phase 1 Withdrawn

Prostatic Neoplasms

NCT03043989 2020-02-17

Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

Phase 1 Terminated

Prostatic Neoplasms

NCT02512458 2020-02-10

CABA-BONE

Phase 2 Completed

Bone Metastatic Prostate Cancer

NCT02379390 2019-06-21

PRIMCAB

Phase 2 Terminated

8 enrolled 8 charts

Prostate Cancer Metastatic

NCT01308567 2019-06-05

FIRSTANA

Phase 3 Completed

1,168 enrolled 17 charts

Prostatic Neoplasms

NCT01668459 2018-12-04

CabB1

Phase 2/3 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT01335204 2018-07-13

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

Phase 1/2 Terminated

4 enrolled 5 charts

Prostatic Neoplasms

NCT01845792 2018-06-04

Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer

Phase 2 Terminated

7 enrolled 10 charts

Prostatic Neoplasms

NCT03356912 2017-12-14

CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy

Phase 2 Unknown

Prostatic Neoplasms

NCT02254785 2017-12-06

Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

Phase 2 Unknown

Prostatic Neoplasms, Castration-Resistant